These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 29109163)

  • 1. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
    Belley A; Arhin FF; Moeck G
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an
    Belley A; Lalonde-Séguin D; Arhin FF; Moeck G
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilizing genomic analyses to investigate the first outbreak of vanA vancomycin-resistant Enterococcus in Australia with emergence of daptomycin non-susceptibility.
    Douglas AP; Marshall C; Baines SL; Ritchie D; Szer J; Madigan V; Chan HT; Ballard SA; Howden BP; Buising K; Slavin MA
    J Med Microbiol; 2019 Mar; 68(3):303-308. PubMed ID: 30663951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Tsai HY; Lee YL; Liu PY; Lu MC; Shao PL; Lu PL; Cheng SH; Ko WC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Lee WS; Shi ZY; Chen YS; Wang FD; Tseng SH; Chen YH; Sheng WH; Lee CM; Chen YH; Liao CH; Hsueh PR
    Int J Antimicrob Agents; 2021 Jul; 58(1):106353. PubMed ID: 33961991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
    Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
    J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
    Arhin FF; Seguin DL; Belley A; Moeck G
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):168-171. PubMed ID: 28733126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
    Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
    J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin-resistant Enterococcus faecium in Algeria: phenotypic and genotypic characterization of clinical isolates.
    Benamrouche N; Guettou B; Henniche FZ; Assaous F; Laouar H; Ziane H; Djennane F; Tiouit D; Bentchouala C; Yamouni F; Rahal K; Tali Maamar H
    J Infect Dev Ctries; 2021 Jan; 15(1):95-101. PubMed ID: 33571151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.
    Carter GP; Harjani JR; Li L; Pitcher NP; Nong Y; Riley TV; Williamson DA; Stinear TP; Baell JB; Howden BP
    J Antimicrob Chemother; 2018 Jun; 73(6):1562-1569. PubMed ID: 29518208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections.
    Woods RJ; Patel TS; Nagel JL; Newton DW; Read AF
    Infect Control Hosp Epidemiol; 2018 Feb; 39(2):226-228. PubMed ID: 29331166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant Enterococcus faecium (VREfm).
    Kelly J; Tysall L; Dewar S
    J Antimicrob Chemother; 2022 Apr; 77(5):1432-1435. PubMed ID: 35165738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid in vivo development of resistance to daptomycin in vancomycin-resistant Enterococcus faecium due to genomic alterations.
    Mollerup S; Elmeskov C; Pinholt M; Sejersen TS; Pedersen MS; Worning P; Frees D; Westh H
    FEMS Microbiol Lett; 2022 Aug; 369(1):. PubMed ID: 35922088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Applicable System for Rapidly Predicting Enterococcus faecium Susceptibility to Vancomycin.
    Wang HY; Chung CR; Chen CJ; Lu KP; Tseng YJ; Chang TH; Wu MH; Huang WT; Lin TW; Liu TP; Lee TY; Horng JT; Lu JJ
    Microbiol Spectr; 2021 Dec; 9(3):e0091321. PubMed ID: 34756065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an
    Jahanbakhsh S; Singh NB; Yim J; Kebriaei R; Smith JR; Lev K; Tran TT; Rose WE; Arias CA; Rybak MJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094136
    [No Abstract]   [Full Text] [Related]  

  • 17. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Cha R; Rybak MJ
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):539-46. PubMed ID: 14596973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and Persistence of Glycopeptide-Resistant
    Rodríguez-Lucas C; Fernández J; Raya C; Bahamonde A; Quiroga A; Muñoz R; Rodicio MR
    Microb Drug Resist; 2022 Feb; 28(2):217-221. PubMed ID: 34705570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
    Belley A; Arhin FF; Sarmiento I; Deng H; Rose W; Moeck G
    Antimicrob Agents Chemother; 2013 Jan; 57(1):205-11. PubMed ID: 23089749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
    Arias CA; Mendes RE; Stilwell MG; Jones RN; Murray BE
    Clin Infect Dis; 2012 Apr; 54 Suppl 3(Suppl 3):S233-8. PubMed ID: 22431854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.